Three-drug treatment shows promise for patients with rare blood cancer BPDCN
July 09, 2026
July 09, 2026
BOSTON, Massachusetts, July 9 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Three-drug treatment shows promise for patients with rare blood cancer BPDCN
*
A three-drug treatment combination led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, in a phase 2 clinical trial led by researchers at Dana-Farber Cancer . . .
* * *
Three-drug treatment shows promise for patients with rare blood cancer BPDCN
*
A three-drug treatment combination led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, in a phase 2 clinical trial led by researchers at Dana-Farber Cancer . . .